Orexigen Therapeutics (OREX)
Orexigen Therapeutics Earnings Yield: -14.64%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
OREX Earnings Yield Rankings
| Overall | 13th percentile | 3738 of 4318 |
| Sector | 30th percentile | 344 of 492 in Healthcare |
| Industry | 24th percentile | 31 of 41 in Drug Manufacturers - Other |
OREX Earnings Yield Range, Past 5 Years
| Minimum | -131.8% | Jun 2007 |
| Maximum | 17.87% | Jun 2008 |
| Average | -36.10% |
About Earnings Yield
Earnings yield is earnings per share from the previous four quarters divided by the share price. It is the reciprocal of the P/E ratio. The earnings yield is quoted as a percentage, which illustrates the percentage of each dollar invested that was earned by the company during the past twelve months.
The earnings yield can be used to compare the earnings of a stock, sector or the whole market against bond yields. Generally, the earnings yields of equities are higher than the yield of risk-free treasury bonds. Financial theorists argue that this difference exists because stock earnings are riskier than bond coupon payments.
If a company has an earnings yield of 64%, investors are purchasing $0.64 of earnings per dollar invested.
Learn More
You may also be interested in these OREX related companies
OREX News
$ARNA rebounds after share offering last week at $5.50 $OREX $VVUS http://stks.co/3vPY
about 9 days ago by EPS_MomentuM
about 9 days ago by EPS_MomentuM
RT @Bleedblue: RT @newkidontheblock FDA follows Adcom rec 80 percent. $orex anyone? Was the 20% it DOES happen.
about 15 days ago by DutchFanBoy
about 15 days ago by DutchFanBoy
$ARNA close above 7$ will be very bullish as market wants a turn around Tuesday $VVUS $OREX $$
about 15 days ago by peterumble
about 15 days ago by peterumble
$ARNA looks stronger day by day means more upside to come yet, a good day will break 8$ this week $VVUS $OREX $$
about 16 days ago by peterumble
about 16 days ago by peterumble
@Bleedblue don't know about dates $orex i do TA mostly very little biotech $study but have a hunch from what i've read it is safer of the 2
about 16 days ago by Good2go
about 16 days ago by Good2go
@Bleedblue agree & the reason that $orex will follow $arna & 1 day possibly have the preferred drug (fda willing that is).
about 16 days ago by Good2go
about 16 days ago by Good2go
@DrNick This is strange, seeing $OREX only has two products in the pipeline... Kind of early move, eh!? ;-)
about 16 days ago by mitrado
about 16 days ago by mitrado
@DrNick $orex nice, thanks for the link. bought some today. not in $arna
about 16 days ago by Good2go
about 16 days ago by Good2go
Arena and Orexigen Compete to Bring First Weight Loss Drug to Market in Nearly 13 Years
May 14, 8:20AM Marketwire
May 14, 8:20AM Marketwire
Bank of America: Key Takeaways from Orexigen Therapeutics' Management Meetings
Apr 11, 10:27AM Benzinga
Apr 11, 10:27AM Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| OREX | 3.415 | -0.06 | -1.59% | 235.06M |
| ORCT | 0.36 | -0.04 | -9.16% | 9.016M |
| ORCL | 26.13 | -0.33 | -1.25% | 132.98B |
| ORCC | 2.27 | -0.03 | -1.30% | 74.34M |
| ORBT | 3.55 | -0.08 | -2.20% | 17.17M |
| ORBK | 10.02 | -0.18 | -1.76% | 441.97M |
| ORBC | 3.23 | -0.04 | -1.22% | 151.89M |
| OMCL | 13.30 | -0.26 | -1.92% | 454.12M |
| OMC | 48.52 | -1.24 | -2.49% | 13.57B |
| OMAB | 15.39 | +0.64 | +4.34% | 654.38M |
